Thyroid cancer is the most common endocrine cancer with 1,690 deaths each year. There are four main types of which the papillary and follicular types together account for >90% followed by medullary cancers with 3% to 5% and anaplastic carcinomas making up < 3%. Epigenetic events of DNA hypermethylation are emerging as promising molecular targets for cancer detection. Our immediate and long term goal is to identify DNA methylation markers for early detection of thyroid cancer. This pilot study comprised of 21 patients to include 11 papillary thyroid cancers (PTC), 2 follicular thyroid cancers (FTC), 5 normal thyroid cases, and 3 hyperthyroid cases. Aberrant promoter methylation was examined in 24 tumor suppressor genes using the methylation specific multiplex ligation-dependent probe amplification (MS-MLPA) assay and in the NIS gene using methylation-specific PCR (MSP). The frequently methylated genes were CASP8 (17/21), RASSF1 (16/21) and NIS (9/21). In the normal samples, CASP8, RASSF1 and NIS were methylated in 5/5, 4/5 and 1/5 respectively. In the hyperthyroid samples, CASP8, RASSF1 and NIS were methylated in 3/3, 2/3 and 1/3 respectively. In the thyroid cancers, CASP8, RASSF1, and NIS were methylated in 9/13, 10/13, and 7/13 respectively. CASP8, RASSF1 and NIS were also methylated in concurrently present normal thyroid tissue in 3/11, 4/11 and 3/11 matched thyroid cancer cases (matched for presence of both normal thyroid tissue and thyroid cancer), respectively. Our data suggests that aberrant methylation of CASP8, RASSF1, and NIS maybe an early change in thyroid tumorigenesis regardless of cell type.
References
[1]
Thyroid cancer. Available online: http://www.cancer.gov/cancertopics/types/thyroid (accessed on 24 February 2011).
[2]
American Cancer Society. Quickfacts. In Thyroid Cancer; American Cancer Society: Atlanta, GA, USA, 2009.
[3]
Stearns, V.; Yamauchi, H.; Hayes, D.F. Circulating tumor markers in breast cancer: Accepted utilities and novel prospects. Breast Cancer Res. Treat. 1998, 52, 239–259.
[4]
Hu, M.I.; Vassilopoulou-Sellin, R.; Lustig, R.; Lamont, J.P. Thyroid and parathyroid cancers. In Cancer Management: A Multidisciplinary Approach, 11th ed.; Pazdur, R., Wagman, L.D., Camphausen, K.A., Hoskins, W.J., Eds.; Congregational Ministries Publishing: Louisville, KY, USA, 2008.
[5]
American Cancer Society. American Cancer Society Cancer Facts and Figures; American Cancer Society: Atlanta, GA, USA, 2005.
[6]
Weber, F.; Eng, C. Gene-expression profiling in differentiated thyroid cancer--a viable strategy for the practice of genomic medicine? Future Oncol. 2005, 1, 497–510.
[7]
Mazzaferri, E.L.; Kloos, R.T. Clinical review 128: Current approaches to primary therapy for papillary and follicular thyroid cancer. J. Clin. Endocrinol. Metab. 2001, 86, 1447–1463.
[8]
Schlumberger, M.J. Papillary and follicular thyroid carcinoma. N. Engl. J. Med. 1998, 338, 297–306.
[9]
Hayes, D.F.; Bast, R.C.; Desch, C.E.; Fritsche, H., Jr.; Kemeny, N.E.; Jessup, J.M.; Locker, G.Y.; Macdonald, J.S.; Mennel, R.G.; Norton, L.; Ravdin, P.; Taube, S.; Winn, R.J. Tumor marker utility grading system: A framework to evaluate clinical utility of tumor markers. J. Natl. Cancer Inst. 1996, 88, 1456–1466.
[10]
Kulasingam, V.; Diamandis, E.P. Strategies for discovering novel cancer biomarkers through utilization of emerging technologies. Nat. Clin. Pract. Oncol. 2008, 5, 588–599.
[11]
Xing, M. Gene methylation in thyroid tumorigenesis. Endocrinology 2007, 148, 948–953.
[12]
Smith, J.A.; Fan, C.Y.; Zou, C.; Bodenner, D.; Kokoska, M.S. Methylation status of genes in papillary thyroid carcinoma. Arch. Otolaryngol. Head Neck Surg. 2007, 133, 1006–1011.
[13]
Hu, S.; Liu, D.; Tufano, R.P.; Carson, K.A.; Rosenbaum, E.; Cohen, Y.; Holt, E.H.; Kiseljak-Vassiliades, K.; Rhoden, K.J.; Tolaney, S.; Condouris, S.; Tallini, G.; Westra, W.H.; Umbricht, C.B.; Zeiger, M.A.; Califano, J.A.; Vasko, V.; Xing, M. Association of aberrant methylation of tumor suppressor genes with tumor aggressiveness and braf mutation in papillary thyroid cancer. Int. J. Cancer 2006, 119, 2322–2329.
[14]
Xing, M.; Cohen, Y.; Mambo, E.; Tallini, G.; Udelsman, R.; Ladenson, P.W.; Sidransky, D. Early occurrence of rassf1a hypermethylation and its mutual exclusion with braf mutation in thyroid tumorigenesis. Cancer Res. 2004, 64, 1664–1668.
[15]
Lazar, V.; Bidart, J.M.; Caillou, B.; Mahe, C.; Lacroix, L.; Filetti, S.; Schlumberger, M. Expression of the na+/i- symporter gene in human thyroid tumors: A comparison study with other thyroid-specific genes. J. Clin. Endocrinol. Metab. 1999, 84, 3228–3234.
[16]
Xing, M.; Usadel, H.; Cohen, Y.; Tokumaru, Y.; Guo, Z.; Westra, W.B.; Tong, B.C.; Tallini, G.; Udelsman, R.; Califano, J.A.; Ladenson, P.W.; Sidransky, D. Methylation of the thyroid-stimulating hormone receptor gene in epithelial thyroid tumors: A marker of malignancy and a cause of gene silencing. Cancer Res. 2003, 63, 2316–2321.
[17]
Ringel, M.D.; Anderson, J.; Souza, S.L.; Burch, H.B.; Tambascia, M.; Shriver, C.D.; Tuttle, R.M. Expression of the sodium iodide symporter and thyroglobulin genes are reduced in papillary thyroid cancer. Mod. Pathol. 2001, 14, 289–296.
[18]
Segev, D.L.; Clark, D.P.; Zeiger, M.A.; Umbricht, C. Beyond the suspicious thyroid fine needle aspirate. A review. Acta. Cytol. 2003, 47, 709–722.
Baloch, Z.W.; Fleisher, S.; LiVolsi, V.A.; Gupta, P.K. Diagnosis of “Follicular neoplasm”: A gray zone in thyroid fine-needle aspiration cytology. Diagn. Cytopathol. 2002, 26, 41–44.
[21]
Yeh, M.W.; Demircan, O.; Ituarte, P.; Clark, O.H. False-negative fine-needle aspiration cytology results delay treatment and adversely affect outcome in patients with thyroid carcinoma. Thyroid 2004, 14, 207–215.
[22]
Putti, T.C.; Bhuiya, T.A.; Wasserman, P.G. Fine needle aspiration cytology of mixed tall and columnar cell papillary carcinoma of the thyroid. A case report. Acta. Cytol. 1998, 42, 387–390.
[23]
Wreesmann, V.B.; Sieczka, E.M.; Socci, N.D.; Hezel, M.; Belbin, T.J.; Childs, G.; Patel, S.G.; Patel, K.N.; Tallini, G.; Prystowsky, M.; Shaha, A.R.; Kraus, D.; Shah, J.P.; Rao, P.H.; Ghossein, R.; Singh, B. Genome-wide profiling of papillary thyroid cancer identifies muc1 as an independent prognostic marker. Cancer Res. 2004, 64, 3780–3789.
[24]
Ruggeri, R.M.; Campenni, A.; Baldari, S.; Trimarchi, F.; Trovato, M. What is new on thyroid cancer biomarkers. Biomark. Insights 2008, 3, 237–252.
[25]
Pingoud-Meier, C.; Lang, D.; Janss, A.J.; Rorke, L.B.; Phillips, P.C.; Shalaby, T.; Grotzer, M.A. Loss of caspase-8 protein expression correlates with unfavorable survival outcome in childhood medulloblastoma. Clin. Cancer. Res. 2003, 9, 6401–6409.
[26]
Yang, Q.; Kiernan, C.M.; Tian, Y.; Salwen, H.R.; Chlenski, A.; Brumback, B.A.; London, W.B.; Cohn, S.L. Methylation of casp8, dcr2, and hin-1 in neuroblastoma is associated with poor outcome. Clin. Cancer. Res. 2007, 13, 3191–3197.
[27]
Harada, K.; Toyooka, S.; Shivapurkar, N.; Maitra, A.; Reddy, J.L.; Matta, H.; Miyajima, K.; Timmons, C.F.; Tomlinson, G.E.; Mastrangelo, D.; Hay, R.J.; Chaudhary, P.M.; Gazdar, A.F. Deregulation of caspase 8 and 10 expression in pediatric tumors and cell lines. Cancer Res. 2002, 62, 5897–5901.
[28]
Wu, Y.; Alvarez, M.; Slamon, D.J.; Koeffler, P.; Vadgama, J.V. Caspase 8 and maspin are downregulated in breast cancer cells due to cpg site promoter methylation. BMC Cancer 2010, 10, 32.
Teitz, T.; Wei, T.; Valentine, M.B.; Vanin, E.F.; Grenet, J.; Valentine, V.A.; Behm, F.G.; Look, A.T.; Lahti, J.M.; Kidd, V.J. Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of mycn. Nat. Med. 2000, 6, 529–535.
[31]
Fulda, S.; Debatin, K.M. Ifngamma sensitizes for apoptosis by upregulating caspase-8 expression through the stat1 pathway. Oncogene 2002, 21, 2295–2308.
[32]
Liedtke, C.; Groger, N.; Manns, M.P.; Trautwein, C. The human caspase-8 promoter sustains basal activity through sp1 and ets-like transcription factors and can be up-regulated by a p53-dependent mechanism. J. Biol. Chem. 2003, 278, 27593–27604.
[33]
Chaudhary, P.M.; Eby, M.T.; Jasmin, A.; Kumar, A.; Liu, L.; Hood, L. Activation of the nf-kappab pathway by caspase 8 and its homologs. Oncogene 2000, 19, 4451–4460.
[34]
Salvesen, G.S. Caspase 8: Igniting the death machine. Structure 1999, 7, R225–R229.
[35]
Zoli, W.; Ulivi, P.; Tesei, A.; Fabbri, F.; Rosetti, M.; Maltoni, R.; Giunchi, D.C.; Ricotti, L.; Brigliadori, G.; Vannini, I.; Amadori, D. Addition of 5-fluorouracil to doxorubicin-paclitaxel sequence increases caspase-dependent apoptosis in breast cancer cell lines. Breast Cancer Res. 2005, 7, R681–R689.
[36]
Ehrhardt, H.; Hacker, S.; Wittmann, S.; Maurer, M.; Borkhardt, A.; Toloczko, A.; Debatin, K.M.; Fulda, S.; Jeremias, I. Cytotoxic drug-induced, p53-mediated upregulation of caspase-8 in tumor cells. Oncogene 2008, 27, 783–793.
[37]
Schagdarsurengin, U.; Gimm, O.; Hoang-Vu, C.; Dralle, H.; Pfeifer, G.P.; Dammann, R. Frequent epigenetic silencing of the cpg island promoter of rassf1a in thyroid carcinoma. Cancer Res. 2002, 62, 3698–3701.
[38]
Hou, P.; Bojdani, E.; Xing, M. Induction of thyroid gene expression and radioiodine uptake in thyroid cancer cells by targeting major signaling pathways. J. Clin. Endocrinol. Metab. 2010, 95, 820–828.
[39]
Venkataraman, G.M.; Yatin, M.; Marcinek, R.; Ain, K.B. Restoration of iodide uptake in dedifferentiated thyroid carcinoma: Relationship to human na+/i-symporter gene methylation status. J. Clin. Endocrinol. Metab. 1999, 84, 2449–2457.
[40]
Boltze, C.; Zack, S.; Quednow, C.; Bettge, S.; Roessner, A.; Schneider-Stock, R. Hypermethylation of the cdkn2/p16ink4a promotor in thyroid carcinogenesis. Pathol. Res. Pract. 2003, 199, 399–404.
[41]
Smanik, P.A.; Ryu, K.Y.; Theil, K.S.; Mazzaferri, E.L.; Jhiang, S.M. Expression, exon-intron organization, and chromosome mapping of the human sodium iodide symporter. Endocrinology 1997, 138, 3555–3558.
[42]
Arturi, F.; Russo, D.; Schlumberger, M.; du Villard, J.A.; Caillou, B.; Vigneri, P.; Wicker, R.; Chiefari, E.; Suarez, H.G.; Filetti, S. Iodide symporter gene expression in human thyroid tumors. J. Clin. Endocrinol. Metab. 1998, 83, 2493–2496.
[43]
Filetti, S.; Bidart, J.M.; Arturi, F.; Caillou, B.; Russo, D.; Schlumberger, M. Sodium/iodide symporter: A key transport system in thyroid cancer cell metabolism. Eur. J. Endocrinol. 1999, 141, 443–457.
[44]
Stephen, J.K.; Vaught, L.E.; Chen, K.M.; Sethi, S.; Shah, V.; Benninger, M.S.; Gardner, G.M.; Schweitzer, V.G.; Khan, M.; Worsham, M.J. Epigenetic events underlie the pathogenesis of sinonasal papillomas. Mod. Pathol. 2007, 20, 1019–1027.
[45]
Stephen, J.K.; Chen, K.M.; Shah, V.; Schweitzer, V.G.; Gardner, G.; Benninger, M.S.; Worsham, M.J. Consistent DNA hypermethylation patterns in laryngeal papillomas. Int. J. Head Neck Surg. 2010, 1, 69–77.
[46]
Nygren, A.O.; Ameziane, N.; Duarte, H.M.; Vijzelaar, R.N.; Waisfisz, Q.; Hess, C.J.; Schouten, J.P.; Errami, A. Methylation-specific mlpa (ms-mlpa): Simultaneous detection of cpg methylation and copy number changes of up to 40 sequences. Nucleic Acids Res. 2005, 33, e128.
Worsham, M.J.; Chen, K.M.; Meduri, V.; Nygren, A.O.; Errami, A.; Schouten, J.P.; Benninger, M.S. Epigenetic events of disease progression in head and neck squamous cell carcinoma. Arch. Otolaryngol. Head Neck Surg. 2006, 132, 668–677.
[49]
Chen, K.; Sawhney, R.; Khan, M.; Benninger, M.S.; Hou, Z.; Sethi, S.; Stephen, J.K.; Worsham, M.J. Methylation of multiple genes as diagnostic and therapeutic markers in primary head and neck squamous cell carcinoma. Arch. Otolaryngol. Head Neck Surg. 2007, 133, 1131–1138.
